治疗心力衰竭的维里西瓜特:系统性审查和元分析
Heng Yang1, Chao Luo1, Wan-Qi Lan1
1Department of Cardiovascular Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang 330008, Jiangxi Province, China.
World journal of clinical cases
|December 22, 2023
概括
维里西瓜特 (10毫克) 通过减少住院治疗和心血管事件,有效治疗慢性心力衰竭. 这一元分析证实了它的疗效和与安慰剂相比有利的安全性.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 心力衰竭 (HF) 代表着一个重要的全球健康和经济负担.
- 维里西瓜特是一种新兴的治疗药物,用于治疗高血压.
研究的目的:
- 进行元分析,评估Vericiguat在慢性心力衰竭患者的疗效和安全性.
- 综合随机对照试验 (RCT) 的数据,以评估Vericiguat对关键临床结果的影响.
主要方法:
- 在PubMed,EMBASE,Web of Science和Cochrane图书馆进行了全面的文献搜索,截至2023年3月.
- 包括4项涉及5919名患者的RCT,独立提取数据和质量评估.
- 使用RevMan5.4进行的元分析,以汇集数据并评估治疗效果.
主要成果:
- 维瑞西瓜特 (10毫克) 显著降低了主要终点 (心血管死亡率或HF住院) (RR=0.91,P=0.01) 和HF住院 (RR=0.92,P=0.05).
- 在心血管死亡,全因死亡,血压,心率或生活质量得分方面没有发现显著差异.
- 韦里西瓜特的安全性与安慰剂相似,症状性低血压和昏迷的增加趋势不显著.
结论:
- 维里西瓜特 (10毫克) 在治疗慢性心力衰竭方面表现出比安慰剂更高的疗效.
- 该药物具有良好的安全性,使其成为慢性心力衰竭患者的可行治疗选择.
更多相关视频
14:35Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
8.5K
09:20Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
Published on: February 13, 2021
6.5K
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
436
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
436
01:22Heart Failure Drugs: Diuretics
394
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
394
01:22Heart Failure Drugs: β-Blockers
341
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
341
01:26Heart Failure Drugs: Inotropic Agents
594
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
594
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
170
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
170
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
2.9K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.9K